BMUS Statement on the Renaming of PCOS to PMOS

4th Jun 2026

BMUS welcomes the publication of the international consensus paper in The Lancet announcing the renaming of Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). 

This landmark change reflects a growing understanding that the condition extends far beyond the ovaries alone. For many years, the term "PCOS" has been recognised as potentially misleading, as not all individuals diagnosed with the condition have polycystic ovarian morphology, and the presence of polycystic ovaries alone does not confirm a diagnosis. The previous terminology often placed disproportionate emphasis on ovarian appearances while underrepresenting the complex endocrine, metabolic, reproductive, dermatological and psychological features that many individuals experience.

The new name, PMOS, better acknowledges the multisystem nature of the condition and highlights the important role of endocrine and metabolic dysfunction. Developed through a rigorous global consensus process involving patients, healthcare professionals, researchers and professional organisations, the change aims to improve understanding, reduce stigma, support earlier diagnosis and encourage more holistic, multidisciplinary care.

For ultrasound professionals, this change is particularly significant. While ultrasound remains an important component of assessment for many patients, ovarian morphology is only one aspect of a much broader clinical picture. The updated terminology helps reinforce the need to consider imaging findings alongside clinical symptoms, biochemical markers and metabolic health.

BMUS recognises this as a positive and progressive step towards improving awareness and support for the millions of people living with this condition worldwide. By adopting terminology that more accurately reflects the full spectrum of its manifestations, healthcare professionals can better communicate the nature of the condition, empower patients with a clearer understanding of their health, and promote more comprehensive pathways of care.

We look forward to supporting the implementation of this change across clinical practice and education as the transition to PMOS progresses over the coming years.